Chembio Board Member Named Winner of Commercialization Award by Purdue
Dr. Peter Kissinger Recognized for Role in Commercializing Purdue Research
MEDFORD, N.Y., Nov. 21, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI) a leader in point-of-care ("POC") diagnostic tests for
infectious diseases, announced today that Peter Kissinger, Ph.D., a member of
the company's board of directors and professor of chemistry at Purdue
University, has received the Outstanding Commercialization Award for Purdue
University for 2013. The award is given annually to a Purdue University
faculty member in recognition of outstanding contributions to, and success
with, commercializing the University's research discoveries.
"It comes as no surprise that Peter's many commercialization accomplishments
have received such recognition," said Lawrence Siebert, Chembio's Chief
Executive Officer. "Chembio is proud to have Peter as a member of our board
and we extend our congratulations to him for this great honor."
Dr. Kissinger is a scientist, entrepreneur, and academic, with a multifaceted
career in biotechnology and biomedical technologies. Dr. Kissinger is a
Professor of Chemistry and Associate Department Head at Purdue University.He
has published more than 230 scientific papers and he is a columnist for the
trade publication Drug Discovery News.Dr. Kissinger is a Fellow of the
American Association of Pharmaceutical Scientists and the American Association
for the Advancement of Science.
Dr. Kissinger has founded multiple bioscience companies, including Phlebotics,
Inc., a medical device company focused on diagnostic information for intensive
care medicine. Dr. Kissinger received a B.S. in Chemistry from Union College,
Schenectady, N.Y., and a Ph.D. in Analytical Chemistry from the University of
North Carolina in Chapel Hill.
More information can be found regarding Dr. Kissinger's receipt of the
Outstanding Commercialization Award for Purdue University at the following
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP®) technology, which has significant
advantages over lateral-flow technologies. This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 200 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U.S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485. For more
information, please visit: www.chembio.com.
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management. Such
statements, which are estimates only, reflect management's current views, are
based on certain assumptions, and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to Chembio's
ability to obtain additional financing and to obtain regulatory approvals in a
timely manner, as well as the demand for Chembio's products. Chembio
undertakes no obligation to publicly update these forward-looking statements
to reflect events or circumstances that occur after the date hereof or to
reflect any change in Chembio's expectations with regard to these
forward-looking statements or the occurrence of unanticipated events. Factors
that may impact Chembio's success are more fully disclosed in Chembio's most
recent public filings with the U.S. Securities and Exchange Commission.
CONTACT: Chembio Diagnostics, Inc.
(631) 924-1135, ext. 125
Vida Strategic Partners (investors)
Stephanie C. Diaz
Press spacebar to pause and continue. Press esc to stop.